Table 1. Characteristics of the studies included in the meta-analysis.
| Year | Author | Treatment | Frq* | Total | Ethnicity | OR (95% CI) | Study endpoints | OR in MTA | Definition of good response | |
| TC vs.TT | CC vs.TT | |||||||||
| 2007 | Brantley [10] | Bev. | 0.55 | 86 | CA | 0.84 (0.17–4.09) | 8.50 (0.93–105.50) | VA (Snellen) | Rspr vs. non-Rspr | Not clearly defined |
| 2007 | Seitsonen [11] | PDT | 0.58 | 88 | CA | 0.66 (0.15–3.08) | 0.62 (0.12–3.34) | VA (Snellen/ETDRS) | Rspr vs. non-Rspr | Not clearly defined |
| 2008 | Klein [12] | AO&Zn | 0.53 | 239 | CA | 1.96 (0.71–6.24) | 5.09 (1.79–16.45) | Progression | Progr. vs. no Progr. | No progression to advanced AMD after treatment |
| 2009 | Feng [13] | PDT | 0.54 | 265 | CA | 1.62 (0.78–3.32) | 1.77 (0.79–3.98) | VA (Snellen) | Rspr vs. non-Rspr | An improved/unchanged VA, or lost <3 lines of vision (final VA ≥6/60) |
| 2009 | Lee [9] | Ran. | 0.54 | 156 | CA | 1.25 (0.94–1.67) | 1.37 (1.01–1.87) | VA, recurrence | Recur. vs. no Recur. | No recurrence in follow-up time (the first 70 days excluded) |
| 2011 | Kloeckener -Gruissem [14] | Ran. | 0.50 | 122 | CA | 0.68 (0.26–1.77) | 2.67 (0.85–8.58) | VA (ETDRS) | Rspr vs. non-Rspr | Improve VA at ≥75th percentile |
| 2011 | Nischler [15] | Bev. | 0.48 | 197 | UD | 1.26 (0.53–2.95) | 2.39 (0.76–8.29) | VA | Rspr vs. non-Rspr | Gained ≥3 lines in reading VA |
| 2011 | Tsuchihashi [16] | PDT | 0.07 | 110 | AA | 1.41 (0.38–5.28) | NA | VA, recurrence | Recur. vs. no Recur. | No recurrence in 1-year after PDT |
| 2012 | McKibbin [17] | Ran. | 0.50 | 104 | CA | 0.41 (0.13–1.19) | 0.42 (0.12–1.48) | VA (ETDRS) | Rspr vs. non-Rspr | More than 5 BCVA letter score gain after 6 months |
| 2012 | Orlin [18] | Ran/Bev | 0.47 | 143 | UD | 1.07 (0.45–2.60) | 1.42 (0.51–3.97) | VA (Snellen) | Rspr vs. non-Rspr | An improved/unchanged VA in ≥1 eye (most recent VA ≥20/200) |
Abbreviations: AA, Asian; AMD, age-related macular degeneration; AO&Zn, antioxidants and Zinc; Bev., bevacizumab; CA, Caucasian; CI, confidence interval; ETDRS, Early Treatment Diabetic Retinopathy Study; Frq, frequency; MAF, minor allele frequency; MTA., meta-analysis; NA, not available; OR, odds ratio; PDT, photodynamic therapy; Progr., progression; Ran., ranibizumab; Recur., recurrence; Rspr, responders; UD, Undeclared; VA, visual acuity.
*
Frequency of the variant C-allele of rs1061170 (T1277C, Y402H). The ancestral allele of rs1061170 is T according to dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1061170).